03674oam 2200577 450 991029835410332120190911103515.01-4899-8002-410.1007/978-1-4899-8002-1(OCoLC)868918491(MiFhGG)GVRL6YWD(EXLCZ)99371000000007369920131030d2014 uy 0engurun|---uuuuatxtccrObesity and breast cancer the role of dysregulated estrogen metabolism /Kristy A. Brown, Evan R. Simpson1st ed. 2014.New York :Springer,2014.1 online resource (ix, 56 pages) illustrations (chiefly color)SpringerBriefs in Cancer Research,2194-1173Description based upon print version of record.1-4899-8001-6 Includes bibliographical references.Introduction -- Estrogens, adiposity and the menopause -- The link between obesity and breast cancer: Epidemiological evidence -- Adipose-derived and obesity-related factors and breast cancer -- Estrogen biosynthesis -- Therapies aimed at breaking the linkage between obesity and breast cancer -- Conclusions.Obesity is a risk factor for breast cancer in older women. A number of adipose-derived and obesity-related factors have been shown to affect tumour cell growth. These include adipokines, insulin, IGF-1 and oestrogens. The majority of obesity-related postmenopausal breast cancers are oestrogen-dependent. Since the ovaries no longer produce oestrogens after menopause, and that circulating levels are negligible, it is evident that it is the oestrogens produced locally within the breast adipose that are responsible for the increased growth of breast cancer cells. Aromatase is the enzyme that converts androgens into oestrogens and its regulation is dependent on the activity of a number of tissue-specific promoters. Targeting oestrogen biosynthesis in obesity may be useful for the prevention of breast cancer. Aromatase inhibitors are efficacious at treating postmenopausal breast cancer and recent studies suggest that they may also be useful in the prevention setting. However, these compounds inhibit the catalytic activity of aromatase and as a consequence lead to a number of undesirable side-effects, including arthralgia and possible cognitive defects due to inhibition of aromatase in the bone and brain, respectively. Novel therapies, such as those employed to treat obesity-associated disease, including anti-diabetics, may prove successful at inhibiting aromatase specifically within the breast. This SpringerBrief will explore all of these issues in depth and the authors are in a unique position to write about this topic, having extensive experience in the field of aromatase research.SpringerBriefs in cancer research.EnzymesBreastCancerEtiologyBreastCancerRisk factorsMetabolismDisordersObesityOncologyEnzymes.BreastCancerEtiology.BreastCancerRisk factors.MetabolismDisorders.Obesity.Oncology.572.6616.99/4071Brown Kristy Aauthttp://id.loc.gov/vocabulary/relators/aut1059858Simpson E. R(Evan R.),MiFhGGMiFhGGBOOK9910298354103321Obesity and Breast Cancer2508876UNINA01127nam0 22002893i 450 VAN0009656720240806100704.38320140127d1960 |0itac50 baitaIT|||| |||||ˆIl ‰condominio di case divise in partiDomenico Riccardo Peretti-GrivaTorino : UTET1960XI590 p. ; 24 cmFondo Tribunale di Napoli.001VAN000048912001 Studi di diritto e procedura civile210 TorinoUtet.Edifici in condominioVANC002982FITorinoVANL00000134721Peretti GrivaDomenico RiccardoVANV035495229195UTET <editore>VANV107949650ITSOL20240906RICABIBLIOTECA DEL DIPARTIMENTO DI GIURISPRUDENZAIT-CE0105VAN00VAN00096567BIBLIOTECA DEL DIPARTIMENTO DI GIURISPRUDENZA00CONS FTA.174 00FTN6109 20140127 Condominio di case divise in parti682530UNICAMPANIA